生物免疫刺激剂对大鼠外周血淋巴细胞和肝大颗粒淋巴细胞生物活性的影响

INFLUENCE OF BIOLOGICAL IMMUNE STIMULANTS ON THE ACTIVITY OF LYMPHOCYTES IN PERIPHERAL BLOOD AND LARGE GRANULAR LYMPHOCYTES IN THE LIVER OF RAT

正常大鼠在体内应用干扰素（ＩＦＮα—２ｂ），卡介苗（ＢＣＧ）或二者联用后，检测外周血淋巴细胞转化率和酸性非特异性酯酶（ＡＮＡＥ）阳性淋巴细胞数量的变化。同时从正常大鼠肝内分离出大颗粒淋巴细胞（ＬＧＬ），体外分别受ＩＦＮα－２ｂ、ＢＣＧ或二者联合作用后，以３Ｈ－ＴｄＲ掺入实验测定生物免疫刺激剂（ＢＩＳ）对ＬＧＬ抗肝癌细胞作用的影响。结果：（１）单用ＩＦＮα－２ｂ对大鼠淋巴细胞母细胞化有一定的抑制作用，抑制率为２１．７％；单用ＢＣＧ使大鼠淋巴细胞转化率提高了２７．９％，二者联用则可消除ＩＦＮα－２ｂ对大鼠淋巴细胞母细胞化的抑制作用。（２）ＩＦＮα－２ｂ、ＢＣＧ或二者联用均使大鼠外周血ＡＮＡＥ阳性淋巴细胞显著增多，其中ＢＣＧ作用强于ＩＦＮα－２ｂ（Ｐ＜０．０１），以ＩＦＮα－２ｂ和ＢＣＧ二者联用的效果最强。（３）ＩＦＮα－２ｂ、ＢＣＧ均可显著增强大鼠肝ＬＧＬ的抑肝癌细胞增殖作用，ＢＣＧ作用较ＩＦＮα－２ｂ强，二者分别使肝ＬＧＬ抑肝癌细胞增殖作用提高了５０％和２２．４％，ＩＦＮα－２ｂ和ＢＣＧ协同作用的效果最强，使肝ＬＧＬ的抑肝癌细胞作用提高了６３％。实验结果为肝癌免疫治疗的最佳选择提供了充分的科学依据。

After the normal rats were treated respectively with IFNα 2b,BCG or combination of both,the rejuvenation rate of lymphocyte and the number of acid α naphthyl acetate esterase(ANAE)positive lymphocytes in peripheral blood were measured.The large granular lymphocytes(LGL)were isolated from rat liver,and were treated respectively with IFNα 2b,BCG or combination of both in vitro,the influence of biological immune stimulants(BIS)on LGL’s cytostatic activity against human SMMC 7721 hepatoma cells were assayed through measuring 3H TdR incorporation into tumor cell DNA.The results showed that:(1)IFNα 2b reduced the rejuvenation rate of lymphocytes by 21.7%,BCG raised it by 27.9%,the combined use of IFNα 2b and BCG resulted in remaining the rejuvenation rate of lymphocytes in normal level.(2)The number of ANAE positive lymphocytes in peripheral blood increased obviously,the effect of BCG was more effective than IFNα 2b(P<0.01),the combination of IFNα 2b and BCG showed the best result.(3)IFNα 2b and BCG could enhance the cytostatic effect of LGL against hepatoma cell obviously,BCG was more effective than IFNα 2b.IFNα 2b and BCG enhanced the cytostatic effect of LGL against hepatoma cell respectively by 22.4% and 50%.The combined use of IFNα 2b and BCG exhibited the best effect,enhancing the anti hepatoma effect of LGL by 63%.The results provided the most adequate scientific foundation for the best application of hepatoma immunotherapy.